Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab
ConclusionOur findings suggest that the short-term impact on OBF varies depending on the drug used for nAMD.
Source: International Ophthalmology - Category: Opthalmology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Eyes | Japan Health | Lucentis | Opthalmology | Ranibizumab Injection | Study